AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
55,000
Employees55,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
55,000
Employees55,000

ABBV Key Statistics

Market cap
378.77B
Market cap378.77B
Price-Earnings ratio
163.55
Price-Earnings ratio163.55
Dividend yield
3.03%
Dividend yield3.03%
Average volume
8.03M
Average volume8.03M
High today
$217.35
High today$217.35
Low today
$213.88
Low today$213.88
Open price
$215.26
Open price$215.26
Volume
8.65M
Volume8.65M
52 Week high
$244.81
52 Week high$244.81
52 Week low
$164.39
52 Week low$164.39

Stock Snapshot

AbbVie(ABBV) stock is priced at $214.45, giving the company a market capitalization of 378.77B. It carries a P/E multiple of 163.55 and pays a dividend yield of 3.0%.

As of 2026-01-17, AbbVie(ABBV) stock has fluctuated between $213.88 and $217.35. The current price stands at $214.45, placing the stock +0.3% above today's low and -1.3% off the high.

The AbbVie(ABBV)'s current trading volume is 8.65M, compared to an average daily volume of 8.03M.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.

ABBV News

Seeking Alpha 14h
Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma

Genmab (GMAB) on Friday announced that its bispecific antibody epcoritamab, marketed as Epkinly in partnership with AbbVie (ABBV), extended patient survival wit...

Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma
TipRanks 14h
Genmab Reports Positive Phase 3 Progression-Free Survival Data for Epcoritamab in Relapsed/Refractory DLBCL

Claim 70% Off TipRanks Premium Genmab ( (GMAB) ) has shared an announcement. On January 16, 2026, Genmab reported topline Phase 3 results from its global EPCO...

TipRanks 14h
AbbVie announces results for epcoritamab from Phase 3 EPCORE DLBCL-1 trial

AbbVie (ABBV) announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcuta...

Analyst ratings

65%

of 31 ratings
Buy
64.5%
Hold
32.3%
Sell
3.2%

More ABBV News

TipRanks 16h
AbbVie Expands Oncology Pipeline With First-in-Human ABBV-711 Trial in Advanced Squamous Tumors

Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...

Simply Wall St 19h
How Investors May Respond To AbbVie $100 Billion U.S. Investment And Drug Pricing Pact

In recent days, AbbVie said it reached a voluntary three-year agreement with the Trump administration to cut prices on select medicines offered through Medicaid...

How Investors May Respond To AbbVie $100 Billion U.S. Investment And Drug Pricing Pact
Nasdaq 1d
AbbVie Stock Dips While Market Gains: Key Facts

The latest trading session saw AbbVie (ABBV) ending at $193.45, denoting a -1.16% adjustment from its last day's close. This move lagged the S&P 500's daily gai...

AbbVie Stock Dips While Market Gains: Key Facts
TipRanks 2d
AbbVie Advances Obesity Pipeline With Completion of First-in-Human GUB014295 Trial

Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...

Simply Wall St 2d
Assessing AbbVie Valuation After Recent Share Price Weakness

Advertisement Event driven look at AbbVie AbbVie (ABBV) has been drawing attention after recent share price moves, with the stock modestly positive over the p...

Assessing AbbVie Valuation After Recent Share Price Weakness
Nasdaq 3d
Ex-Dividend Reminder: AbbVie, Dime Community Bancshares and MidWestOne Financial Group

Looking at the universe of stocks we cover at Dividend Channel, on 1/16/26, AbbVie Inc (Symbol: ABBV), Dime Community Bancshares Inc (Symbol: DCOM), and MidWest...

Ex-Dividend Reminder: AbbVie, Dime Community Bancshares and MidWestOne Financial Group
Benzinga 4d
AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines

AbbVie Inc. (NYSE:ABBV) on Monday announced a voluntary agreement with the Trump administration to advance access and affordability further. AbbVie said it wil...

AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .